Vivesto AB (SE:VIVE)
:VIVE
Want to see SE:VIVE full AI Analyst Report?
VIVE Stock Chart & Stats
kr0.08
>-kr0.01(-0.59%)
At close: 4:00 PM EST
kr0.08
>-kr0.01(-0.59%)
Day’s Range― - ―
52-Week Rangekr7.00 - kr27.82
Previous CloseN/A
Volume772.68K
Average Volume (3M)410.92K
Market Cap
kr98.54M
Enterprise Valuekr46.37M
Total Cash (Recent Filing)kr31.48M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.38
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding11,071,369
10 Day Avg. Volume214,919
30 Day Avg. Volume410,918
Financial Highlights & Ratios
PEG Ratio8.38
Price to Book (P/B)58.31
Price to Sales (P/S)0.00
P/FCF Ratio-165.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Manageable DebtMeasured indebtedness (debt-to-equity ~0.10; modest absolute debt) provides a durable financial buffer vs. highly leveraged peers. Lower interest and refinancing burden preserves flexibility to fund clinical programs, seek partnerships, and manage R&D cadence without immediate solvency pressure.
Proprietary Drug-delivery Platforms And Oncology FocusA specialized platform strategy and oncology focus create a structural competitive edge: IP in formulation and delivery can be licensed or partnered, enabling milestone and royalty streams. This asset-light, partnership-friendly model supports long-term value creation without immediate commercial build-out.
Lean Operating Structure (small Headcount)An extremely lean headcount structurally reduces fixed overhead and extends cash runway when combined with outsourced R&D and CRO relationships. This capital-efficient operating model helps the company prioritize clinical development and licensing activities before scaling staff or commercial operations.
Bears Say
Persistent Cash Burn And Negative Operating Cash FlowSustained negative operating cash flow is a durable constraint: repeated burn (~-34.0M in 2025) will necessitate recurring external funding or non-dilutive partnerships. That ongoing need raises dilution risk, complicates long-term planning and can slow trial progress absent secured financing.
No Reported Revenue In 2024–2025A structural absence of commercial revenue in recent years means there is no validated, recurring income to underwrite operations. This increases reliance on capital markets and partnerships, prevents durable margin visibility, and leaves the company exposed if fundraising conditions tighten.
Materially Reduced Equity / Weakened Capital CushionA sharp fall in equity and persistently negative returns (~-27% ROE) erode the firm's buffer against further losses. The diminished capital cushion limits balance-sheet flexibility, raises vulnerability to setbacks, and increases the probability and potential size of dilutive capital raises to sustain operations.
Vivesto AB News
VIVE FAQ
What was Vivesto AB’s price range in the past 12 months?
Vivesto AB lowest stock price was kr7.00 and its highest was kr27.82 in the past 12 months.
What is Vivesto AB’s market cap?
Vivesto AB’s market cap is kr98.54M.
When is Vivesto AB’s upcoming earnings report date?
Vivesto AB’s upcoming earnings report date is Aug 13, 2026 which is in 56 days.
How were Vivesto AB’s earnings last quarter?
Vivesto AB released its earnings results on May 07, 2026. The company reported -kr0.838 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.838.
Is Vivesto AB overvalued?
According to Wall Street analysts Vivesto AB’s price is currently Overvalued.
Does Vivesto AB pay dividends?
Vivesto AB does not currently pay dividends.
What is Vivesto AB’s EPS estimate?
Vivesto AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vivesto AB have?
Vivesto AB has 11,071,369 shares outstanding.
What happened to Vivesto AB’s price movement after its last earnings report?
Vivesto AB reported an EPS of -kr0.838 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Vivesto AB?
Currently, no hedge funds are holding shares in SE:VIVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vivesto AB
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its leading human oncology product is Apealea (paclitaxel micellar), designed for the treatment of ovarian cancer. The company's pipeline for human health also includes Docetaxel micellar, a patented formulation combining the cytotoxin docetaxel with XR-17, which is currently in Phase 1b clinical trials for prostate cancer, as well as Cantrixil for addressing ovarian cancer. For animal health, Vivesto provides Paccal Vet, leveraging its XR-17 encapsulation technology to deliver paclitaxel for canine mastocytoma, and Doxophos Vet, a proprietary doxorubicin formulation used to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) until its name change to Vivesto AB in March 2022.
Technical Analysis
AlzeCure Pharma AB
―
Gabather AB
―
Klaria Pharma Holding AB
―
Nanexa AB
―
Enorama Pharma AB
―